ALGN vs GH

ALGN's Piotroski F-Score of 4/9 indicates weak financial health, signaling potential operational inefficiencies despite stable profitability. The absence of an Altman Z-Score raises concern about default risk, though the company's extremely low debt/equity ratio (0.03) and strong liquidity support financial stability. The stock trades near its intrinsic value of $166.68 but at a premium to the Graham Number ($84.93), reflecting high growth expectations. Analysts maintain a 'buy' consensus with a target price of $201.57, suggesting upside, though recent insider selling and inconsistent earnings surprises temper enthusiasm.

Guardant Health presents a classic high-growth, pre-profitability profile, evidenced by a stable but mediocre Piotroski F-Score of 4/9. While the company demonstrates impressive top-line momentum with 39.4% YoY revenue growth and a strong current ratio of 4.84, it continues to operate with significant negative margins and negative shareholder equity. The stark divergence between the 'Strong Buy' analyst consensus and the bearish insider selling suggests a disconnect between institutional growth projections and internal sentiment. Overall, the stock is a speculative growth play where valuation is driven by future market penetration rather than current fundamental value.